康柏西普联合依帕司他治疗糖尿病视网膜病变患者的临床研究  

Clinical trial of conbercept combined with epalrestat in the treatment of patients with diabetic retinopathy

作　　者：康建芳[1] 孙昊[1] 冯军[1] KANG Jian-fang;SUN Hao;FENG Jun(Department of Ophthalmology,the Second People's Hospital of Huai'an,Huai'an 223002,Jiangsu Province,China)

机构地区：[1]淮安市第二人民医院眼科,江苏淮安223002

出　　处：《中国临床药理学杂志》2021年第9期1048-1051,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察康柏西普联合依帕司他治疗糖尿病视网膜病变患者的临床研究。方法将104例患者用随机数字表法分为试验组52例和对照组52例。对照组给予依帕司他50 mg,每天3次,连续用药14 d;试验组在对照组的基础上给予玻璃体腔一次性注射药物康柏西普0.1 mL。比较2组患者治疗后的临床疗效、肿瘤坏死因子-α(TNF-α)、视网膜厚度、总抗氧化能力(TAOC)、超氧化物歧化酶(SOD)、血糖指标、最佳矫正视力变化情况(BCVA)及药物不良反应发生情况。结果治疗后,试验组和对照组的总有效率分别为94.23%(49例/52例),78.85%(41例/52例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的BCVA分别为0.39±0.11,0.24±0.12,TNF-α分别为(12.68±1.62),(17.35±2.04)ng·L^(-1),视网膜厚度分别为(123.8±32.8),(129.6±32.9)μm, TAOC分别为(19.97±2.62),(16.21±1.74)U·mL^(-1),SOD分别为(89.54±10.24),(81.02±9.87)U·mL^(-1),空腹血糖分别为(5.01±0.58),(5.92±0.64)mmol·L^(-1),餐后血糖分别为(8.22±0.79),(8.76±1.21)mmol·L^(-1),糖化血红蛋白水平分别为(6.23±0.84)%,(6.79±0.81)%,差异均有统计学意义(均P<0.05)。2组患者用药期间均未出现明显的药物不良反应。结论康柏西普联合依帕司他对糖尿病视网膜病变患者的疗效显著,且安全性高。Objective To investigate the effects of conbercept and epalrestat in the treatment of patients with diabetic retinopathy. Methods A total of 104 patients were divided into treatment group(52 cases) and control group(52 cases) by random number table. Patients in control group were given epalrestat 50 mg, tid, for 14 d. Patients in treatment group were given one-time intravitreal injection of conbercept 0.1 mL, on the basis of control group. The clinical effect, tumor necrosis factor-α(TNF-α), retinal thickness, total antioxidant capacity(TAOC), superoxide dismutase(SOD), blood glucose index, best corrected vision acuity(BCVA) changes and adverse drug reactions in two groups were compared. Results After treatment, the total effective rates in treatment group and control group were 94.23%(49 cases/52 cases), 78.85%(41 cases/52 cases), with significant difference(P<0.05). After treatment, the BCVA in treatment group and control group were 0. 39 ± 0. 11 and 0. 24 ± 0. 12,TNF-α were( 12. 68 ± 1. 62),( 17. 35 ± 2. 04) ng·L^(-1),the thickness of the retina were( 123. 8 ± 32. 8),( 129. 6 ± 32. 9) μm,TAOC were( 19. 97 ± 2. 62),( 16. 21 ± 1. 74) U·mL^(-1),SOD were( 89. 54 ± 10. 24),( 81. 02 ± 9. 87) U · mL^(-1),fasting blood glucose were( 5. 01 ± 0. 58),( 5. 92 ± 0. 64)mmol·L^(-1),postprandial blood glucose were( 8. 22 ± 0. 79),( 8. 76 ± 1. 21) mmol·L^(-1),glycosylated hemoglobin levels were( 6. 23 ± 0. 84) % and( 6. 79 ± 0. 81) %,all with significant difference( all P < 0. 05). There was no obvious adverse drug reaction in two groups. Conclusion The combination of conbercept and epalrestat is effective and safe for patients with diabetic retinopathy.

关 键 词：康柏西普 依帕司他 糖尿病视网膜病变患者 

分 类 号：R988.1[医药卫生—药品]